A new class of drugs called gamma-secretase modulators works to reduce the buildup of toxic proteins in the brains of people with Alzheimer’s disease, giving doctors hope that these medications may offer effective new treatments for the devastating brain ailment. Results of advanced-stage testing of one of these drugs, called Flurizan, failed to show any benefit, though this unfortunate failure does not signal that other drugs, based on the same principle—called gamma-secretase modulation—will fail.
Researchers at the Mayo Clinic report that gamma-secretase modulators work to reduce the production of long pieces of a protein called beta-amyloid that builds up in the brains of those with the disease. These drugs also appear to promote the production of shorter forms of beta-amyloid that may inhibit the longer forms from sticking together and forming brain-damaging clumps, at least in experimental models.
Doctors have long known that beta-amyloid builds up in the brains of people with Alzheimer’s disease. But scientists still don’t know exactly why or how this occurs, and how it may lead to the onset of memory loss and dementia.
Beating Back Beta-Amyloid
The Fisher Center Foundation funds scientists who continue to be at the forefront of research into the understanding of beta-amyloid, a protein that is at the root of Alzheimer’s disease. Beta-amyloid forms dense protein deposits called plaques found in the brains of people with Alzheimer’s. These and other forms of beta-amyloid are believed to cause most of the devastating, degenerative changes in the Alzheimer’s brain. Fisher Center scientists were among the first to define the specific steps by which beta-amyloid is produced, and their discovery that pharmacological substances can interrupt this process set off a worldwide race to develop drugs to inhibit beta-amyloid buildup.
Fisher scientists’ beta-amyloid research is now focused on a protein called amyloid precursor protein (APP). Fisher scientists are unraveling the process by which APP is broken down to form beta-amyloid. Their immediate goal is to develop ways to slow the accumulation of plaque and other forms of beta-amyloid in the brain and reduce their toxic effects on nerve cells, moving much closer to a cure for Alzheimer’s disease. In fact, Fisher Center scientists are making significant progress in developing therapies aimed at reducing the production of toxic beta-amyloid, an achievement that might ultimately prevent, slow or even cure the disease.
Fisher scientists have also recently discovered how beta-amyloid damages communication between brain cells and how fibers connecting brain cells can be grown or made to shrink. With this understanding, it may be possible to devise therapies that protect the brain even when beta-amyloid production goes awry.
Beta-amyloid by itself it not necessarily bad. It is formed from a larger protein called amyloid precursor protein, or APP, that can be snipped into shorter segments by proteins called secretases. One of these secetases is called gamma secretase. It acts on a fragment of APP, shearing it like a pair of molecular scissors into smaller fragments of beta-amyloid of varying length.
One resulting form of beta-amyloid, consisting of 42 protein building blocks called amino acids, appears to be particularly toxic to the brain. This 42-amino acid form
of beta-amyloid is the main form that builds up in the brains of those with Alzheimer’s disease to form plaques. A hallmark of Alzheimer’s is the formation of these plaques, which are believed to damage neurons in complex ways that are not yet fully understood.
But beta-amyloid also exists in shorter forms, like the 38- and 40-amino acid segments that appear to be less harmful. These shorter segments may even be beneficial, helping to prevent the longer, and toxic, 42-amino acid form from sticking together.
How the New Drugs Work
The new drugs, the gamma secretase modulators, are believed to act on APP, rather than the gamma secretase enzyme directly. As a result, when gamma secretase shears the larger APP protein, it tends to form shorter snippets of nontoxic beta-amyloid. At the same time, less of the toxic form of beta-amyloid is produced. These findings appeared in the June 12 issue of the scientific journal, Nature.
“So, as these compounds lower the amount of the bad, longer beta-amyloid peptides in the brain, they increase the quantity of shorter beta-amyloid peptides that may protect against development of Alzheimer’s disease,” said the study’s senior author, Todd Golde, M.D., Ph.D., Chair of the Department of Neuroscience at the Mayo Clinic in Jacksonville.
“In a very general sense the action of these gamma secretase modulators on beta-amyloid might be analogous to some cholesterol-lowering drugs that can lower LDL, the bad cholesterol that sticks to your arteries, but not lower HDL, the good cholesterol,” Dr. Golde said.
There is also some evidence that the gamma secretase modulators actually stick to the toxic beta-amyloid already in the brain, keeping it from clumping together.
“Surprisingly, this means that these compounds may do three things that may be beneficial with respect to Alzheimer’s disease: they inhibit production of long beta-amyloid, may block aggregation of beta-amyloid, and increase production of shorter beta-amyloid peptides that may in turn inhibit beta-amyloid aggregation,” said the study’s lead investigator, Thomas Kukar, Ph.D.
Because these experimental drugs lower levels of toxic beta-amyloid, they are sometimes also referred to as selective amyloid lowering agents, or SALAs.
Despite Flurizan Failure, Hope Remains
The first new gamma secretase modulator to complete clinical trial testing was Flurizan, known by the generic name tarenflurbil. An advanced Phase 3 clinical trial of the drug in 1,684 patients from 131 medical centers was recently completed. Unfortunately, the drug failed, and further testing has been discontinued by the company that owns it, Myriad Genetics.
These results contrast with results of recently released data from an earlier, mid-stage (Phase 2) trial in patients with mild Alzheimer’s disease who took Flurizan and showed marginally less decline in their ability to carry out everyday tasks than those taking a dummy pill. The larger, more recent Phase 3 trial showing no benefit is considered more reliable, however, because of its size, and is considered the “final word” on the subject.
Currently available drugs for Alzheimer’s, like Aricept, Razadyne, Exelon, and Namenda, may ease symptoms for a time in some patients. But these drugs do not modify the long-term worsening of the disease.
“Millions of people suffer from Alzheimer’s disease, and treatment options are limited,” says Paul Greengard, Ph.D., the Fisher Center for Alzheimer’s Disease Research director at The Rockefeller University. “Existing drugs may mask symptoms for a time but do nothing to stop the relentless downward progression of Alzheimer’s. What is needed are safe and effective medications that will halt, or even reverse, the relentless progression of the underlying disease.”
Researchers hope that disease-modifying drugs that inhibit beta-amyloid may alter the progressive memory loss and other cognitive problems that devastate those with Alzheimer’s disease. It may take years, however, before any drugs that alter production of beta-amyloid are proven safe and effective against Alzheimer’s disease.
There is still hope for these kinds of drugs, though. According to Dr. Golde, “Anytime we gain an increased understanding of the precise molecular action of a drug, that enhances our ability to make better drugs.” Still, the process of drug testing is complex. A drug may seem to work well in an experimental model but fail when given to a human being, the ultimate testing ground.
Source: www.ALZinfo.org. Preserving Your Memory: The Magazine of Health and Hope; Fall 2008. Reviewed by William J. Netzer, Ph.D., Fisher Center for Alzheimer’s Disease Research at The Rockefeller University.